Gland Pharma Limited (BOM:543245)

Gland Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	3,571	19,089	3,188	4,925	1,695
Short-Term Investments	15,817	18,539	27,720	25,107	11,427
Trading Asset Securities	-	-	1,549	-	-
Cash & Short-Term Investments	19,388	37,628	32,457	30,031	13,122
Cash Growth	-48.48%	15.93%	8.08%	128.86%	82.06%
Accounts Receivable	16,482	9,587	12,097	6,710	6,018
Other Receivables	641.42	771.8	825.85	732.4	621.1
Receivables	17,123	10,360	12,928	7,445	6,644
Inventory	16,763	19,782	12,292	12,882	7,714
Prepaid Expenses	384.65	138.22	141.61	108.83	91.22
Other Current Assets	2,793	1,100	702.63	769.81	891.99
Total Current Assets	56,452	69,008	58,521	51,236	28,463
Property, Plant & Equipment	38,302	17,361	16,804	12,920	11,566
Long-Term Investments	6,545	-	2,000	-	-
Goodwill	2,423	-	-	-	-
Other Intangible Assets	1,122	116.61	125.35	-	-
Long-Term Deferred Tax Assets	504.37	-	-	-	-
Other Long-Term Assets	1,265	1,290	886.04	804.02	831.83
Total Assets	106,612	87,775	78,336	64,961	40,860
Accounts Payable	8,627	5,874	4,629	3,963	2,491
Accrued Expenses	1,385	477.42	461.14	358.33	445.96
Short-Term Debt	1,671	-	-	-	-
Current Portion of Long-Term Debt	461.21	5.6	1.12	1.35	8.91
Current Portion of Leases	177.05	1.49	1.49	1.62	1.26
Current Income Taxes Payable	516.37	9.85	179.79	286.9	107.23
Current Unearned Revenue	344.92	8.12	8.87	7.37	7.37
Other Current Liabilities	800.72	915.35	539.34	506.22	528.56
Total Current Liabilities	13,984	7,291	5,820	5,125	3,590
Long-Term Debt	1,065	32.61	38.21	39.34	40.69
Long-Term Leases	346.79	4.83	6.61	7.64	9.25
Long-Term Unearned Revenue	404.86	-	-	-	-
Long-Term Deferred Tax Liabilities	2,201	842.03	877.6	738.81	740.54
Other Long-Term Liabilities	298.28	17.33	17.33	17.33	17.33
Total Liabilities	19,374	8,188	6,760	5,928	4,398
Common Stock	164.71	164.7	164.3	163.59	154.95
Additional Paid-In Capital	19,292	19,284	18,954	18,401	5,890
Retained Earnings	67,910	60,185	52,375	40,258	30,288
Comprehensive Income & Other	-128.27	-46.81	83.32	209.71	129.06
Shareholders' Equity	87,238	79,587	71,576	59,032	36,462
Total Liabilities & Equity	106,612	87,775	78,336	64,961	40,860
Total Debt	3,722	44.53	47.43	49.95	60.11
Net Cash (Debt)	15,666	37,584	32,410	29,982	13,062
Net Cash Growth	-58.32%	15.96%	8.10%	129.53%	82.91%
Net Cash Per Share	95.10	228.22	196.97	189.42	84.30
Filing Date Shares Outstanding	164.71	164.7	164.3	163.59	154.95
Total Common Shares Outstanding	164.71	164.7	164.3	163.59	154.95
Working Capital	42,468	61,717	52,701	46,111	24,873
Book Value Per Share	529.65	483.22	435.64	360.85	235.32
Tangible Book Value	83,694	79,471	71,451	59,032	36,462
Tangible Book Value Per Share	508.13	482.51	434.87	360.85	235.32
Land	9,305	634.58	627.07	435.68	435.68
Buildings	5,934	3,328	3,203	2,492	2,246
Machinery	30,449	18,844	16,940	11,366	10,783
Construction In Progress	2,379	1,772	1,807	3,378	1,885

Source: S&P Global Market Intelligence. Standard template. Financial Sources.